144 related articles for article (PubMed ID: 27324149)
1. Advanced imaging of tau pathology in Alzheimer Disease: New perspectives from super resolution microscopy and label-free nanoscopy.
Schierle GS; Michel CH; Gasparini L
Microsc Res Tech; 2016 Aug; 79(8):677-83. PubMed ID: 27324149
[TBL] [Abstract][Full Text] [Related]
2. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
Thal DR; Attems J; Ewers M
J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
[TBL] [Abstract][Full Text] [Related]
3. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
Watanabe H
Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
[TBL] [Abstract][Full Text] [Related]
4. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.
Brier MR; Gordon B; Friedrichsen K; McCarthy J; Stern A; Christensen J; Owen C; Aldea P; Su Y; Hassenstab J; Cairns NJ; Holtzman DM; Fagan AM; Morris JC; Benzinger TL; Ances BM
Sci Transl Med; 2016 May; 8(338):338ra66. PubMed ID: 27169802
[TBL] [Abstract][Full Text] [Related]
5. Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET.
Matsuda H; Shigemoto Y; Sato N
Jpn J Radiol; 2019 Nov; 37(11):735-749. PubMed ID: 31493197
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of
Honer M; Gobbi L; Knust H; Kuwabara H; Muri D; Koerner M; Valentine H; Dannals RF; Wong DF; Borroni E
J Nucl Med; 2018 Apr; 59(4):675-681. PubMed ID: 28970331
[TBL] [Abstract][Full Text] [Related]
7. Molecular imaging of dementia.
Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
[TBL] [Abstract][Full Text] [Related]
8. Molecular targets in the rational design of AD specific PET tracers: tau or amyloid aggregates?
Rojo LE; Gaspar PA; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):652-8. PubMed ID: 21605040
[TBL] [Abstract][Full Text] [Related]
9. New Beginnings in Alzheimer's Disease: The Most Prevalent Tauopathy.
Hernández F; Llorens-Martín M; Bolós M; Pérez M; Cuadros R; Pallas-Bazarra N; Zabala JC; Avila J
J Alzheimers Dis; 2018; 64(s1):S529-S534. PubMed ID: 29562521
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
11. Amyloid imaging: Past, present and future perspectives.
Villemagne VL
Ageing Res Rev; 2016 Sep; 30():95-106. PubMed ID: 26827784
[TBL] [Abstract][Full Text] [Related]
12. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
13. [Tau Positron Emission Tomography].
Higuchi M
Brain Nerve; 2017 Jul; 69(7):819-823. PubMed ID: 28739996
[TBL] [Abstract][Full Text] [Related]
14. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.
Okamura N; Furumoto S; Harada R; Tago T; Yoshikawa T; Fodero-Tavoletti M; Mulligan RS; Villemagne VL; Akatsu H; Yamamoto T; Arai H; Iwata R; Yanai K; Kudo Y
J Nucl Med; 2013 Aug; 54(8):1420-7. PubMed ID: 23857514
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
16. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A
Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371
[TBL] [Abstract][Full Text] [Related]
17. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
[TBL] [Abstract][Full Text] [Related]
18. Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer's disease-related microvascular cerebral amyloid angiopathy.
Merlini M; Wanner D; Nitsch RM
Acta Neuropathol; 2016 May; 131(5):737-52. PubMed ID: 26988843
[TBL] [Abstract][Full Text] [Related]
19. [Development of Disease-modifying Therapy for Alzheimer's Disease].
Akiyama H
Brain Nerve; 2016 Apr; 68(4):463-72. PubMed ID: 27056864
[TBL] [Abstract][Full Text] [Related]
20. Tau PET Imaging.
Higuchi M
Adv Exp Med Biol; 2019; 1184():217-230. PubMed ID: 32096041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
